Callan Capital’s Unity Biotechnology UBX Stock Holding History

Callan Capital’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,500	Closed	-$244K	–	55
2018 Q4	$244K	Buy	+1,500	New	+$199K	0.09%	51

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Callan Capital's UBX Position: Q1 2019 in Review

Callan Capital sold out of Unity Biotechnology (UBX) in Q1 2019, closing a stake of 1,500 shares — an estimated $244K sold.

Callan Capital first reported a position in UBX in Q4 2018 and held it in 1 quarter. The position peaked at $244K in Q4 2018. 57 funds tracked by Wall St. Rank hold UBX as of Q1 2019.

Callan Capital reported no remaining Unity Biotechnology position as of Q1 2019 after selling out during the quarter.
Callan Capital sold 1,500 Unity Biotechnology shares in Q1 2019, an estimated $244K.
Callan Capital first reported a position in Unity Biotechnology in Q4 2018 and held it in 1 quarter.
Callan Capital's Unity Biotechnology position peaked at $244K in Q4 2018.
57 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2019.

Based on Callan Capital's 13F filing for Q1 2019, filed 14 May 2019.